Q-omics provides the consensus-scored DZANK1 profile across patient tissues and cancer cell-line models. DZANK1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DZANK1 is differentially expressed in 11, with the highest sampling consensus in KIRP. Additionally, DZANK1 RNA expression shows 20,081 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KIRP, and UVM as cancer lineages where DZANK1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DZANK1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DZANK1 survival associations across molecular data types. DZANK1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (9) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DZANK1 RNA expression–survival associations across cancer types. High DZANK1 expression shows unfavorable associations in KIRC, LGG, ACC and LIHC, but favorable associations in LUAD and READ. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for DZANK1 RNA expression.
This table summarizes DZANK1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRP for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for DZANK1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DZANK1 shows lower tumor expression in THCA and KICH and higher tumor expression in KIRP, BLCA, LIHC and HNSC. The KIRP box plot shows higher DZANK1 RNA expression in tumor versus normal tissue (log2 FC = +0.790, t-test p < 0.001).
This table shows molecular features associated with DZANK1 in patient tissues and cancer cell lines. In patient samples, DZANK1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, DZANK1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BONE.
